linjc16/ctgov huggingface dataset:
Predictors of Recurrence for High Risk Endometrial Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This study will analyze whether there is any difference in recurrence and survival rates among the patients who received different adjuvant therapies.

Detailed Description
-----------------
The incidence of endometrial cancer is gradually increasing nowaday. The postoperative treatment of high-risk endometrial cancer is also inconsistent. Besides, the recurrence of high-risk endometrial cancer is high.The investigators retrospective study will analyze the factors associated with recurrence of endometrial cancer, especially for different adjuvant therapies.

Official Title
-----------------
Predictors of Recurrence for High Risk Endometrial Cancer Patients

Conditions
-----------------
High-risk Endometrial Cancer

Intervention / Treatment
-----------------
* Drug: adjuvant therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with high risk stage I endometrial cancer and all patients with stage II and stage III endometrial cancer and who underwent therapy in Far Eastern Memorial Hospital from 2009/01/01 2019/09/17. Exclusion Criteria: Patients with stage I endometrial cancer do not have high risk factors.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factors affecting overall survival | Factors affecting overall survival | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factors affecting progression-free survival | Factors affecting progression-free survival | 10 years |
Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to evaluate the effect of CPAP over the incidence of cardiovascular events and diagnosis of arterial hypertension in patients with sleep apnea. The hypothesis of the study is the following: The existence of sleep disordered breathing in the general population is associated to an increased incidence of arterial hypertension and to an increased risk of suffering cardiovascular disease. CPAP corrects respiratory disorders during sleep. Treatment with CPAP in subjects with sleep disordered breathing without daytime sleepiness reduces the incidence of systemic arterial hypertension and cardiovascular complications. The end points of the study are new diagnosis of arterial hypertension and new cardiovascular events. All patients, after randomization, will be followed for three years.

Official Title
-----------------
Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness

Conditions
-----------------
Sleep Apnea, Hypertension, Cardiovascular Diseases

Intervention / Treatment
-----------------
* Device: CPAP (Continuous Positive Airway Pressure)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Epworth <10 Apnea-Hypopnea Index ≥20 Exclusion Criteria: Presence of any chronic disease Presence of cardiovascular disease Refusal to sign informed consent Drug addiction and/or alcoholism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: CPAP (Continuous Positive Airway Pressure)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of hypertension |  |  | 
| Incidence of cardiovascular events |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between hypertension and sleep apnea/hypopnea syndrome (SAHS) severity |  |  | 
| Relationship between cardiovascular events and SAHS severity |  |  |
Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial

Study Overview
=================
Brief Summary
-----------------
Despite few scientific evidence that could support the use of ketamine in adult patients undergoing acute bronchospasm requiring mechanical ventilation (MV), ketamine is largely employed in this setting. The aim of this study is therefore assess more definitively the real benefit of using ketamine in patients with severe bronchospasm, requiring ICU stay and need for MV in order to establish or refute the use of this drug as standard therapy in these cases.

Official Title
-----------------
Ketamine Efficacy for Acute Severe Bronchospasm in Mechanically Ventilated-critically Ill Patients: a Randomized Controlled Trial

Conditions
-----------------
Critical Illness, Asthma, Bronchospasm

Intervention / Treatment
-----------------
* Drug: Ketamine
* Drug: Fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with acute exacerbation of COPD or status asthmaticus, undergoing controlled mechanical ventilation acute bronchospasm, defined as airway resistance value (Rsr max) greater than 12, use of inhaled therapy with bronchodilators and systemic corticosteroids patients requiring the use of continuous intravenous sedation for optimization of ventilation Exclusion Criteria: contraindication or history of previous adverse events with the use of the studied drugs other diagnostic potential Rsr increase of not causing bronchospasm (bronchial obstruction, acute respiratory distress syndrome adult, pulmonary fibrosis)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ketamine<br>Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h) | Drug: Ketamine<br>* Active treatment<br>|
| Active Comparator: Fentanyl<br>Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h) | Drug: Fentanyl<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bronchospasm improvement | Maximal airway resistance reduction in hour 3-post beginning of drug infusion | 3 hours post beginning of drug infusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bronchospasm improvement | Maximal airway resistance reduction in 24th hour post beginning of drug infusion | 24 hours post beginning of drug infusion | 
| Time to weaning | Time (in days) to first spontaneous breathing trial post randomization up to 28 days | Time (in days) to first spontaneous breathing trial post randomization up to 28 days |
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the prognostic factors of acute leukemia patients and to invent the molecular genetic test for sensitive detection of minimal residual disease, and thereby this study would contribute to plan the risk adapted treatment. Patients will have samples of blood and/or bone marrow collected during diagnosis process, treatment and/or thereafter

Conditions
-----------------
Acute Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with acute leukemia in Severance Hospital. Both genders of 16 Years and older sign a written informed consent document Exclusion Criteria: No comprehension or willingness to sign a written informed consent document.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival (OS) is defined as the time from date of diagnosis until death due to any cause within the follow-up period. Surviving patients are censored at date of last contact. | 10years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression-free survival (PFS) is defined as survival without disease progression or relapse; patients alive without disease progression or relapse are censored on the last assessment date. Median OS and PFS are calculated using Kaplan-Meier estimates with a 95% confidence interval. | 10years | 
| Treatment-related mortality | Treatment-related mortality was defined as death unrelated to refractory or progressive disease occurring before first remission was achieved, or any death in complete remission | 10years | 
| Complete remission rate | Response assessment is performed according to the criteria reported by BD Cheson et al. (Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia) | 10 years |
Gesture Behavior and Knowledge on Low Back Pain Among Nurses

Study Overview
=================
Brief Summary
-----------------
The aim of the proposed study is to evaluate knowledge on low back pain and gesture behavior among nurses with low back pain using validated measures and compare the findings to those from nurses without back pain.

Detailed Description
-----------------
A controlled, cross-sectional study will be carried out with 100 nurses (50 with low back pain and 50 without low back pain). The following assessment measures will be employed: Visual analogue scale (VAS) for pain, Gesture Behavior Test (GBT), Low Back Pain Knowledge Questionnaire (LKQ), Roland Morris Questionnaire and the SF-36.

Official Title
-----------------
Assessment of Gesture Behavior and Knowledge on Low Back Pain Among Nurses

Conditions
-----------------
Low Back Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-specific chronic low back pain, Performance in the hospital sector (hospitals, emergency rooms and/or intensive care units, Hourly load of at least 6 hours per day, Low back pain on most days in the last three months, Pain greater than 3 cm in visual analog scale (VAS). Exclusion Criteria: Dispute, Previous surgery of the spine, Pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental<br> | |
| Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gesture behavior |  | One week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge among low back pain |  | One week | 
| Roland Morris Questionnaire | Used health status measure for low back pain | One week | 
| SF-36 | Quality of life by SF-36 | One week | 
| Visual analogue scale (VAS) for pain | Evaluation pain | One week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nurses, Low back pain, Gesture behavior, Knowlegde
Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States

Study Overview
=================
Brief Summary
-----------------
Retrospective, cohort study chart review in patients with hypercoagulable states.

Detailed Description
-----------------
Retrospective, cohort study chart review in patients at Methodist Health System Data will be pulled on all patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019

Official Title
-----------------
Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States

Conditions
-----------------
Hypercoagulable States

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ≥ 18 year-old Patients with diagnosis of hypercoagulable state identified by ICD-9/ICD-10 codes Patients who were prescribed DOACs or VKA for primary or secondary prevention of thrombosis Exclusion Criteria: Patients with FDA-approved indications of oral anticoagulants including atrial fibrillation or treatment/prevention of thrombotic events unrelated to specified hypercoagulable states Patients with incomplete electronic medical records

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retrospective Cohort<br>All patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019 | Other: Observational<br>* Retrospective chart review<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rates of thrombotic events during the study period | Rates of thrombotic events during the study period | Jan 1,2015 - Dec 31st, 2019 | 
| Rates of hemorrhagic events during the study period | Rates of hemorrhagic events during the study period | Jan 1,2015 - Dec 31st, 2019 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rates of DOAC prescribing for thrombosis prevention in hypercoagulable states | Rates of DOAC prescribing for thrombosis prevention in hypercoagulable states | Jan 1,2015 - Dec 31st, 2019 |
Effects of Caffeine in Tinnitus

Study Overview
=================
Brief Summary
-----------------
Caffeine intake is reported by many authors to enhance the perception of tinnitus. The aim of this study is to determine the effects of 1 month caffeine intake reduction in the scores of validated questionnaire Tinnitus Handicap Inventory (THI) and in a visual-analog scale (VAS).

Detailed Description
-----------------
A group of 50 patients who takes more than 3 small cups (50 ml) of caffeine daily and have tinnitus will be asked to reduce caffeine intake for 1 month. Scores of THI and VAS will be taken before and after this period.

Official Title
-----------------
Effects of Caffeine Consumption on Tinnitus Perception

Conditions
-----------------
Tinnitus

Intervention / Treatment
-----------------
* Dietary Supplement: caffeine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: tinnitus for more than 6 months THI > 38 no central acting drugs in the last 6 months tympanogram type A-n daily intake of caffeine greater than 150 ml Exclusion Criteria: vascular and muscular tinnitus concomitant TMJ disorders abnormal otoscopy mixed and conductive hearing losses Ménière disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: caffeine|caffeine daily intake will be reduced form 150 ml per day|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tinnitus Handicap Inventory |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analog Scale |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tinnitus, caffeine
AMENDTM Mitral Valve Repair System, Annuloplasty Ring Applied in a Transcatheter Method

Study Overview
=================
Brief Summary
-----------------
A multi center study to evaluate the safety of the AMENDTM Mitral Valve Repair System and its ability to reduce mitral regurgitation. AMEND device is an annuloplasty ring implanted in a minimally invasive trans-catheter method.

Official Title
-----------------
AMEND I Study - for the Valcare Medical AMEND TM Mitral Valve Repair System

Conditions
-----------------
Mitral Regurgitation

Intervention / Treatment
-----------------
* Device: AMEND Mitral Valve Repair System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient age ≥18 The patient requires mitral valve annuloplasty for mitral regurgitation without the need for concomitant cardiovascular surgical procedures NYHA functional capacity ≥2 The subject is high risk to undergo a mitral valve surgery as assessed by the center heart team The patient is willing to comply with study procedures and is available to return to the implant center for follow-up visits. The patient is willing to provide Informed consent Exclusion Criteria: Cardiac or non-cardiac major or progressive disease, which in the investigator's discretion produces an unacceptable increased risk to the patient. Life expectancy of less than twelve months. Heavily calcified annulus or leaflets. Previous or active endocarditis. Active infection. A previously implanted prosthetic mitral valve or annuloplasty ring/band. The patient is contraindicated to general anesthesia. Pregnant (urine HCG test result positive) or lactating patient. Drug or alcohol abuse. Participation in concomitant research studies of investigational products that will interfere with the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AMEND<br> | Device: AMEND Mitral Valve Repair System<br>* Annuloplasty ring applied in a transcatheter method<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety - Freedom from major SAE's at 30 days following procedure | Freedom from major SAE's at 30 days following procedure | 30 days | 
| Technical success of implantation | Ring location and attachment based on echocardiography | End of procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety - Freedom from major SAE's at 6 months following procedure | Freedom from major SAE's at 6 months following procedure | 6 months |
Validation of Hemorrhoidal Bleeding Score

Study Overview
=================
Brief Summary
-----------------
The principal manifestation of hemorrhoidal disease is bleeding; however the severity evaluation is today based on prolapsus (Goligher classification) and bleeding factor is not included. Even if there was some rare score including bleeding in literature , none of them were validated. The aim of the study is first validation of bleeding score .

Official Title
-----------------
Validation of Hemorrhoidal Bleeding Score

Conditions
-----------------
Hemorrhoid Bleeding

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age>18 years consulting for hemorroidal bleeding accept to participate Exclusion Criteria: paraplegic or hemiplegic patient Misunderstanding of the French language

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assessment of bleeding score |  | 1 day |